Results 181 to 190 of about 62,914 (286)

Resilience Ontologies in Veterinary Science: How They Shape the Way We Address Resilience. [PDF]

Vet Sci
Keens Caballero H, Browning H, Lambton S, Maye D, Roe E.   +4 more
europepmc   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Correction: Behl et al. Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme. <i>Cancers</i> 2021, <i>13</i>, 2765. [PDF]

Cancers (Basel)
Behl T, Sharma A, Sharma L, Sehgal A, Singh S, Sharma N, Zengin G, Bungau S, Toma MM, Gitea D, Babes EE, Pusta CTJ, Bumbu AG.   +12 more
europepmc   +1 more source

How diverse are the STEM disciplines? Comparative study of representation, retention, and attrition of underrepresented groups in chemistry, physics, and biological sciences

, 2020
Mike Stieff, Stephanie Werner
openaire   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Kinship Trouble: What, When, Where, Why, and How-and So What? [PDF]

Camb Archaeol J
Cveček S, Raghavan M, Bickle P.
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Exploring health care learners' perceptions of AI integration in the curriculum: a survey tool and findings. [PDF]

BMC Med Educ
Chang L, Polansky M, Yi D, MacDowell M, Sreedhar R, Mosher D, Schwartz A.   +6 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Exposomics Crosses the Rubicon: Let the Building Begin. [PDF]

Environ Sci Technol
Miller GW, Habre R, Patel CJ.
europepmc   +1 more source